retatrutide clinical trial retatrutide drug VisualAbstract: reduces body weight by 17.5% in patients with obesity Seeking Differentiation Through a Triple

Survodutide also reduced waist circumference, an indicator of metabolic health

This application was not for the President, White House spokesman Kush Desai wrote on X, calling suggestions it was Trump baseless speculation. White House communications director Steven Cheung accused the outlet of peddling falsehoods. (Lizzy Lawrence, the STAT reporter who investigated the alleged retatrutide case, says she reached out multiple times to federal health officials and the White House but did not get direct answers before publication.) A separate White House account accused commentators of spreading bulls*** from the usual suspects by linking Trump to the reported drug request

PlexusDx supports continuous access across all 50 states without membership fees

Phase 3 may identify more effective titration strategies that improve both efficacy and adherence

In the TRIUMPH-1 Phase 3 trial, participants on the 12 mg dose lost an average of 28.3% of their body weight at 80 weeks, and up to 30.3% at 104 weeks in the study extension

Do not do this without laboratory confirmation